US 11,980,648 B2
Compositions including ginsenoside 20(S)-Rg3 and methods of using ginsenoside 20(S)-Rg3 to inhibit alpha herpesvirus
Stephen Wright, Murfreesboro, TN (US); Shannon Smith, Murfreesboro, TN (US); Karen Maynard, Murfreesboro, TN (US); and Elliot Altman, Rockvale, TN (US)
Assigned to MIDDLE TENNESSEE STATE UNIVERSITY, Murfreesboro, TN (US)
Filed by MIDDLE TENNESSEE STATE UNIVERSITY, Murfreesboro, TN (US)
Filed on Jun. 4, 2021, as Appl. No. 17/338,882.
Claims priority of provisional application 63/036,380, filed on Jun. 8, 2020.
Prior Publication US 2021/0379132 A1, Dec. 9, 2021
Int. Cl. A61K 36/258 (2006.01); A61K 31/52 (2006.01); A61K 31/522 (2006.01); A61K 31/662 (2006.01); A61K 31/675 (2006.01); A61K 31/704 (2006.01); A61K 31/7125 (2006.01); A61P 31/22 (2006.01)
CPC A61K 36/258 (2013.01) [A61K 31/52 (2013.01); A61K 31/522 (2013.01); A61K 31/662 (2013.01); A61K 31/675 (2013.01); A61K 31/704 (2013.01); A61K 31/7125 (2013.01); A61P 31/22 (2018.01)] 20 Claims
 
1. A method of treating a herpes simplex virus-1 (HSV-1) infection in a mammal in need thereof, the method comprising administering to the mammal a composition comprising an effective amount of the ginsenoside 20(S)-Rg3, wherein 20(S)-Rg3 is at least 80 wt % of the total weight of ginsenosides present in the composition.